Asthma treatment: 'Magic bullets which seek their own targets'

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 62, Issue 6, 2007, Pages 605-610

  Tarantini, F ^a   Baiardini, I ^a   Passalacqua, G ^a   Braido, F ^a   Canonica, G W ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Asthma; Monoclonal antibodies; Omalizumab

Indexed keywords

ALTRAKINCEPT; CD4 ANTIGEN; CELL ADHESION MOLECULE; CLENOLIXIMAB; CORTICOSTEROID; ETANERCEPT; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; KELIXIMAB; MEPOLIZUMAB; NATALIZUMAB; OMALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIGEN ANTIBODY REACTION; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYMPTOM;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS; HUMANS; IMMUNOGLOBULIN E; QUALITY OF LIFE;

EID: 34248547414     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2007.01390.x     Document Type: Review

References (33)

1. Larche M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003 111 : 450 463.
2. Reddy MP, Kinney CA, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P et al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol 2000 164 : 1925 1933.
3. Kon OM, Sihra BS, Loh LC, Barkans J, Compton CH, Barnes NC et al. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. Eur Respir J 2001 18 : 45 52.
4. Erzurum SC. Inhibition of tumor necrosis factor alpha for refractory asthma. N Engl J Med 2006 354 : 754 758.
5. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W et al. Tumor necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005 60 : 1012 1018.
6. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006 354 : 697 708.
7. Van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 172 : 465 469.
8. Cianci R, Cammarota G, Raducci F, Pandolfi F. The impact of biological agents interfering with receptor/ligand binding in the immune system. Eur Rev Med Pharmacol Sci 2005 9 : 305 314.
9. Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res 2001 2 : 66 70.
10. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000 356 : 2144 2148.
11. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003 167 : 1655 1659 Epub 2003 Mar 20.
12. Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003 349 : 2334 2339 M, Fischer S, Plotz SG, Ring J. Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab). Br J Dermatol 2004 151 : 1103 1104.
13. Bryan SA, O'Connor BJ, Matti S, Leckie MJ, Kanabar V, Khan J et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000 356 : 2149 2153.
14. Bochner BS, Schleimer RP. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev 2001 179 : 5 15.
15. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA et al. International natalizumab multiple sclerosis trial group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003 348 : 15 23.
16. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P et al. Natalizumab for active Crohn's disease. N Engl J Med 2003 348 : 24 32.
17. Podolsky DK. Selective adhesion-molecule therapy and inflammatory bowel disease - a tale of Janus? N Engl J Med 2005 353 : 1965 1968.
18. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005 353 : 362 368.
19. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005 353 : 369 374.
20. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005 353 : 375 381.
21. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006 354 : 924 933.
22. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001 18 : 254 261.
23. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005 60 : 309 316.
24. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004 125 : 1378 1386.
25. Buhl R, Hanf G, Soler M, Bensch G, Wolfe J, Everhard F et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002 20 : 1088 1094.
26. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescent with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004 114 : 265 269.
27. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004 59 : 709 717.
28. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006 CD003559.
29. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999 318 : 593 596 DY, Sampson HA, Yunginger JW, Burks AW Jr., Schneider LC, Wortel CH et al. Avon longitudinal study of parents and children study team. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003 348 : 986 993 F, Doudou O, Gaouar H, Le Gros V, Bourdeix I, Guyomarch-Cocco L et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004 113 : 360 361.
30. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002 109 : 274 280.
31. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006 117 : 134 140.
32. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006 54 : 68 72.
33. Schwartz RS. Paul Ehrlich's magic bullets. N Engl J Med 2004 350 : 1079 1080.